Scientist I/II – Neurology – Biosystems

Full time

Framingham, MA

The Scientist I/II (the final role will depend and the experience level of the candidate) will report to the Neurology Program Lead and will work as part of a multidisciplinary team on drug development efforts to modulate activities of targets identified by Berg Interrogative Biology® Platform and on evaluating the efficacy of novel drug candidates for Parkinson’s and other neurodegenerative diseases.


  • Develop cell-based and biochemistry assays for phenotypic screens (low to medium throughput) and potency assays to validate novel drug candidates.
  • Design and execute in vitro studies to demonstrate compound pharmacodynamics and support the development of early drug candidates and lead molecules.
  • Generate and utilize molecular biology reagents (including CRISPR gene-editing tools) for the mechanism of action studies and to develop screening models.
  • Critically analyze data and communicate findings effectively to multidisciplinary team members and management.
  • Perform the full spectrum of laboratory activities including experimental design, assay development, and manage deliverables.
  • Other duties as assigned


  • Requires a Ph.D. in neuroscience, pharmacology, biochemistry, or related fields, postdoctoral training and industry experience preferred.
  • Robust understanding of neurological disease mechanisms, particularly in the areas of Parkinson’s disease and neurodegeneration in general.
  • Proven track record of scientific achievements.
  • Strong laboratory skills, particularly in the areas of molecular biology, biochemistry, and cell-based assays.
  • Experience with pluripotent stem cells and differentiation protocols are required.
  • Demonstrated ability to work in an interdisciplinary team and experience supervising and training technical staff.
  • Strong work ethic and excellent oral/written communication skills are essential.

BERG in the News!

BERG is making headlines.  Click here to see the latest breaking news, interviews, and press releases.